Eli Lilly and CompanyLLYNYSE
LOADING
|||
Price to Sales: Premium Valuation
Above historical average, strong compound growth.
Left:
||||
Price-to-sales ratio
Latest
15.44
↑ 86% above average
Average (9y)
8.30
Historical baseline
Range
High:15.44
Low:3.82
CAGR
+14.2%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | 15.44 | +0.5% |
| 2023 | 15.36 | +26.1% |
| 2022 | 12.18 | +30.9% |
| 2021 | 9.30 | +41.3% |
| 2020 | 6.58 | +16.7% |
| 2019 | 5.64 | +1.9% |
| 2018 | 5.53 | +24.4% |
| 2017 | 4.45 | +16.6% |
| 2016 | 3.82 | -18.2% |
| 2015 | 4.67 | - |